TABLE 3. COVID-19 vaccine introduction, platform used, prioritized groups, coverage, vaccination scheme and booster doses, by country, December 2021 to September 2022.
|
Country |
Date vaccine introduced |
Manufacturer (vaccine or vaccines) |
Vaccination priority groups |
Coverage goal (%) |
Coverage (%) of primary schedule vaccination by epidemiological week 35, 2022 |
Booster dose |
Heterologous vaccination |
|---|---|---|---|---|---|---|---|
|
Argentina |
December 2020 |
AstraZeneca (Vaxzevria) China National Biotec Group (BIBP-CorV) CanSinoBio (Ad5-nCoV) Gamaleya (Sputnik V) Janssen (Ad26.COV2.S) Moderna (mRNA-1273) Pfizer–BioNTech (Comirnaty) Serum Institute of India (Covishield) |
Health workers Older adults |
95 |
82.8 |
Yes |
Yes |
|
Belize |
March 2021 |
AstraZeneca (Vaxzevria) China National Biotec Group (BIBP-CorV) Janssen (Ad26.COV2.S) Pfizer–BioNTech (Comirnaty) Serum Institute of India (Covishield) |
Health workers Older adults Patients with comorbidities Essential workers not in health care |
70 |
54.2 |
Yes |
No |
|
Brazil |
January 2021 |
AstraZeneca (Vaxzevria) Janssen (Ad26.COV2.S) Pfizer–BioNTech (Comirnaty) Sinovac (CoronaVac) |
Health workers Older adults |
90 |
76.9 |
Yes |
Yes |
|
Costa Rica |
December 2020 |
AstraZeneca (Vaxzevria) Moderna (mRNA-1273) Pfizer–BioNTech (Comirnaty) |
Health workers Older adults Patients with comorbidities Essential workers not in health care |
70 |
81.6 |
Yes |
Yes |
|
Panama |
January 2021 |
AstraZeneca (Vaxzevria) Pfizer–BioNTech (Comirnaty) |
Health workers Older adults Patients with comorbidities |
70 |
71.7 |
Yes |
Yes |
|
Peru |
February 2021 |
AstraZeneca (Vaxzevria) China National Biotec Group (BIBP-CorV) Moderna (mRNA-1273) Pfizer–BioNTech (Comirnaty) |
Health workers Older adults Patients with comorbidities |
80 |
84.3 |
Yes |
Yes |
Source: Table prepared by the authors based on the results of their study.